Compare Eli Lilly And Co (LLY) vs Macy's Inc (M) Price & Performance

Eli Lilly (LLY) trades at $1,176.69, down 1.01% on the day, amid a bullish technical outlook and strong fundamental performance. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 consensus. Revenue surged to $65.18B in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing growth prospects.

The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include elevated valuation multiples and competitive pressures in the pharmaceutical sector. With a consensus price target of $1,350, upside potential exists, but investors should weigh execution risks against the company's innovation pipeline.

Macy's stock trades at $22.61, down 0.79% on the day, with strong technical momentum indicated by bullish moving averages. The company demonstrates improving fundamentals with three consecutive quarterly earnings beats and a 'Bold New Chapter' strategy driving digital transformation. Valuation metrics appear attractive with P/E of 8.35 and P/S of 0.27, while profitability shows recovery with ROE of 15.99% and net margin improvement to 3.29%.

The outlook remains cautiously optimistic with analyst consensus at $24.25 representing 7% upside potential. Key opportunities include digital growth initiatives and dividend sustainability, while risks involve retail sector headwinds and uneven quarterly performance. The stock offers value characteristics with turnaround potential, supported by improved cash flow generation and balance sheet strength.